Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer
10.3760/cma.j.cn371439-20231109-00028
- VernacularTitle:胃癌免疫治疗疗效预测及预后标志物的研究进展
- Author:
Yulan LIU
1
;
Haiyan JING
;
Jing SUN
;
Wei SONG
;
Dan SHA
Author Information
1. 山东中医药大学第二临床医学院，济南 250355
- Keywords:
Stomach neoplasms;
Immunotherapy;
Forecasting;
Biomarkers, tumor;
Prognosis
- From:
Journal of International Oncology
2024;51(3):175-180
- CountryChina
- Language:Chinese
-
Abstract:
The high intra- and inter-tumor heterogeneity of gastric cancer leads to a great difference in the immunotherapy efficacy and the prognosis among patients. Several biomarkers, including programmed death-ligand 1, human epidermal growth factor receptor 2, the features of tumor microenvironment, the peripheral blood inflammatory markers and Claudin18.2 have predictive value in the immunotherapy efficacy and the prognosis of gastric cancer patients, which might help the clinicians find the potential patients who will benefit from immunotherapy, and achieve the goal of precision medicine.
